Validea's guru fundamental report indicates HIMS & HERS HEALTH INC (HIMS), a large-cap growth stock in the Biotechnology & Drugs sector, received an 83% rating from its Quantitative Momentum Investor model, based on Wesley Gray's strategy. This score signifies 'some interest' in the stock, driven by its strong and consistent intermediate-term relative performance, aligning with a prominent quantitative investment approach.
HIMS & HERS HEALTH INC (HIMS) has been identified as a noteworthy large-cap growth stock by Validea's Quantitative Momentum Investor model, which is based on the strategy of recognized quantitative expert Wesley Gray. The stock achieved a score of 83%, a rating that indicates 'some interest' from the model, as it surpasses the 80% threshold but falls short of the 90% level for a 'strong interest' signal. The positive rating is primarily driven by the stock's strong and consistent intermediate-term relative performance, specifically passing the 'Twelve Minus One Momentum' test. However, the model's evaluation was not uniformly positive; HIMS received 'Neutral' ratings for 'Return Consistency' and 'Seasonality'. This suggests that while the primary momentum factor is strong, the stock's performance may exhibit some inconsistencies or lack predictable seasonal patterns, preventing it from achieving a top-tier score within this specific quantitative framework.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
